$Hims & Hers Health(HIMS.US)
Novo Nordisk Partnership was the primary driver of the March rally was the announcement of a strategic partnership with Novo Nordisk (NVO), ending a legal dispute. The deal allows Hims & Hers to offer Novo’s FDA-approved GLP-1 medications (like Wegovy and Ozempic) on its platform. This marks a critical strategic shift from selling compounded drugs to a branded pharmaceutical model.
This resolves a major regulatory and legal overhang, provides access to legitimate, high-demand drugs, and could significantly boost revenue and credibility .